Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Experimental and real-world evidence supporting the computational repurposing of bumetanide for APOE4-related Alzheimer’s disease
Alice Taubes, Phil Nova, Kelly A. Zalocusky, et al.
Nature Aging (2021) Vol. 1, Iss. 10, pp. 932-947
Open Access | Times Cited: 87

Showing 1-25 of 87 citing articles:

APOE4/4 is linked to damaging lipid droplets in Alzheimer’s disease microglia
Michael S. Haney, Róbert Pálovics, Christy Munson, et al.
Nature (2024) Vol. 628, Iss. 8006, pp. 154-161
Open Access | Times Cited: 153
Deep generative molecular design reshapes drug discovery
Xiangxiang Zeng, Fei Wang, Yuan Luo, et al.
Cell Reports Medicine (2022) Vol. 3, Iss. 12, pp. 100794-100794
Open Access | Times Cited: 143
Insights into Alzheimer’s disease from single-cell genomic approaches
Mitchell H. Murdock, Li‐Huei Tsai
Nature Neuroscience (2023) Vol. 26, Iss. 2, pp. 181-195
Open Access | Times Cited: 100
Induced pluripotent stem cells (iPSCs): molecular mechanisms of induction and applications
Jonas Cerneckis, Hongxia Cai, Yanhong Shi
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 68
Neuronal APOE4 removal protects against tau-mediated gliosis, neurodegeneration and myelin deficits
Nicole Koutsodendris, Jessica Blumenfeld, Ayushi Agrawal, et al.
Nature Aging (2023) Vol. 3, Iss. 3, pp. 275-296
Open Access | Times Cited: 65
Leveraging electronic health records and knowledge networks for Alzheimer’s disease prediction and sex-specific biological insights
Alice Tang, Katherine P. Rankin, Gabriel Cerono, et al.
Nature Aging (2024) Vol. 4, Iss. 3, pp. 379-395
Open Access | Times Cited: 25
Artificial intelligence and open science in discovery of disease-modifying medicines for Alzheimer’s disease
Feixiong Cheng, Fei Wang, Jian Tang, et al.
Cell Reports Medicine (2024) Vol. 5, Iss. 2, pp. 101379-101379
Open Access | Times Cited: 20
DeepDrug as an expert guided and AI driven drug repurposing methodology for selecting the lead combination of drugs for Alzheimer’s disease
Victor O. K. Li, Yang Han, Tushar Kaistha, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access | Times Cited: 2
CNS pharmacology of NKCC1 inhibitors
Wolfgang Löscher, Kai Kaila
Neuropharmacology (2021) Vol. 205, pp. 108910-108910
Open Access | Times Cited: 59
Adult hippocampal neurogenesis and its impairment in Alzheimer’s disease
Thomas A. Kim, Michelle D. Syty, Kaitlyn Wu, et al.
动物学研究 (2022) Vol. 43, Iss. 3, pp. 481-496
Open Access | Times Cited: 52
Chronic Kidney Disease and Cognitive Impairment: The Kidney-Brain Axis
Zuoquan Xie, Siyu Tong, Xingkun Chu, et al.
Kidney Diseases (2022) Vol. 8, Iss. 4, pp. 275-285
Open Access | Times Cited: 45
Endometriosis in the era of precision medicine and impact on sexual and reproductive health across the lifespan and in diverse populations
Linda C. Giudice, Tomiko Oskotsky, Simileoluwa Falako, et al.
The FASEB Journal (2023) Vol. 37, Iss. 9
Open Access | Times Cited: 33
Cation-Chloride Cotransporters KCC2 and NKCC1 as Therapeutic Targets in Neurological and Neuropsychiatric Disorders
Patricia Lam, Julia Newland, Richard L. M. Faull, et al.
Molecules (2023) Vol. 28, Iss. 3, pp. 1344-1344
Open Access | Times Cited: 29
Neuronal ApoE4 in Alzheimer’s disease and potential therapeutic targets
Lan Zhang, Yiyuan Xia, Yuran Gui
Frontiers in Aging Neuroscience (2023) Vol. 15
Open Access | Times Cited: 23
High-throughput target trial emulation for Alzheimer’s disease drug repurposing with real-world data
Chengxi Zang, Hao Zhang, Jie Xu, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 23
Multi-target drugs for Alzheimer's disease
Bengisu Turgutalp, Çağhan Kızıl
Trends in Pharmacological Sciences (2024) Vol. 45, Iss. 7, pp. 628-638
Closed Access | Times Cited: 14
Taming neuroinflammation in Alzheimer's disease: The protective role of phytochemicals through the gut−brain axis
Yoonsu Kim, Jinkyu Lim, Jisun Oh
Biomedicine & Pharmacotherapy (2024) Vol. 178, pp. 117277-117277
Closed Access | Times Cited: 14
Seizures exacerbate excitatory: inhibitory imbalance in Alzheimer’s disease and 5XFAD mice
Aaron J Barbour, Sarah Gourmaud, Eunjoo Lancaster, et al.
Brain (2024) Vol. 147, Iss. 6, pp. 2169-2184
Closed Access | Times Cited: 11
A paradoxical switch: the implications of excitatory GABAergic signaling in neurological disorders
Colin J. McArdle, Alana A. Arnone, Chelcie F. Heaney, et al.
Frontiers in Psychiatry (2024) Vol. 14
Open Access | Times Cited: 10
Harnessing EHR data for health research
Alice Tang, Sarah Woldemariam, Silvia Miramontes, et al.
Nature Medicine (2024) Vol. 30, Iss. 7, pp. 1847-1855
Closed Access | Times Cited: 9
Integrating gene expression and clinical data to identify drug repurposing candidates for hyperlipidemia and hypertension
Patrick Wu, QiPing Feng, V. Eric Kerchberger, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 37
Ten challenges for clinical translation in psychiatric genetics
Eske M. Derks, Jackson G. Thorp, Zachary F. Gerring
Nature Genetics (2022) Vol. 54, Iss. 10, pp. 1457-1465
Closed Access | Times Cited: 31
Functional excitatory to inhibitory synaptic imbalance and loss of cognitive performance in people with Alzheimer’s disease neuropathologic change
Pietro Scaduto, Julie C. Lauterborn, Conor D. Cox, et al.
Acta Neuropathologica (2022) Vol. 145, Iss. 3, pp. 303-324
Open Access | Times Cited: 31
Clinical relevance of animal models in aging-related dementia research
Pranesh Padmanabhan, Jürgen Götz
Nature Aging (2023) Vol. 3, Iss. 5, pp. 481-493
Closed Access | Times Cited: 17
A framework for translating tauopathy therapeutics: Drug discovery to clinical trials
Howard Feldman, Jeffrey L. Cummings, Adam L. Boxer, et al.
Alzheimer s & Dementia (2024) Vol. 20, Iss. 11, pp. 8129-8152
Open Access | Times Cited: 6
Page 1 - Next Page

Scroll to top